Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Evaluierung von EXL01, einem neuen lebenden biotherapeutischen Produkt zur Verhinderung des Wiederauftretens einer Clostridioides-difficile-Infektion bei Hochrisikopatienten (LIVEDIFF)

19. Oktober 2026 aktualisiert von: Hospices Civils de Lyon

Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors.

Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI.

In this context, fecal microbiota transplantation (FMT) has been validated for over 10 years for the prevention of recurrence in multi-recurrent CDI. The principle of FMT is based on the use of a pharmaceutical preparation made from the stool of a healthy donor, administered within the digestive tract of a patient for therapeutic purposes.

Currently, in the case of multiple recurrences, it is the recommended first-line treatment (from 2 recurrences) and the most effective, with a clinical efficacy preventing recurrence of CDI in 69% to 89% of cases at 8 weeks post-treatment, with a good safety profile.

Among the microbial factors promoting CDI, the loss of the bacterial species Faecalibacterium prausnitzii constitutes a specific therapeutic target. F. prausnitzii is a commensal bacterium of the human gut, making up nearly 5% of the fecal microbiota, and has been shown to be associated with an individual's state of health. A drop in its relative abundance is associated with an increased risk of numerous diseases, such as Crohn's disease and colorectal cancer. In CDI, F prausnitzii is greatly diminished. Moreover, low abundance of F. prausnitzii is predictive of C. difficile recurrence. Its abundance in stools is increased after FMT and is also predictive of response to treatment. From a pathophysiological point of view, one of the preventive effects of F. prausnitzii on recurrence would be mediated by its ability to hydrolyze the bile acids involved in the germination of C. difficile spores.

The aim of this Phase I/II trial is to assess the efficacy and safety of oral administration of EXL01, a single isolated unmodified strain of F. prausnitzii, in preventing CDI recurrence in high-risk patients at W8. The study will be conducted in 2 parts. The phase I (Part A) is planned to include 6 patients. The phase II (Part B) will include 50 patients in two arms (25 patients respectively in the placebo and EXL01 arm).

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

56

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Annecy, Frankreich
        • Noch keine Rekrutierung
        • CH Annecy Genevois Service de Maladies infectieuses
        • Kontakt:
        • Hauptermittler:
          • Emilie PIET, MD
      • Clermont-Ferrand, Frankreich, 63003
        • Rekrutierung
        • Service d'hépato-gastroentérologie - CHU Estaing
        • Kontakt:
        • Hauptermittler:
          • Julien SCANZI, MD
      • Grenoble, Frankreich
        • Rekrutierung
        • CHU Grenoble Service Maladies infectieuses et tropicales
        • Kontakt:
        • Hauptermittler:
          • Salomé GALLET, MD
      • Lille, Frankreich
        • Rekrutierung
        • CHU Lille Unité des Maladies Infectieuses et tropicales
        • Kontakt:
        • Hauptermittler:
          • Sarah STABLER, MD
      • Lyon, Frankreich, 69004
        • Rekrutierung
        • Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse
        • Kontakt:
        • Hauptermittler:
          • Nicolas BENECH, MD
        • Kontakt:
      • Marseille, Frankreich
        • Rekrutierung
        • APHM La Timone Service de Maladies infectieuses
        • Kontakt:
        • Hauptermittler:
          • Nadim CASSIR, MD
      • Paris, Frankreich, 75012
        • Rekrutierung
        • Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP)
        • Kontakt:
        • Hauptermittler:
          • Paul MCLELLAN, MD
      • Saint-Etienne, Frankreich, 42100
        • Rekrutierung
        • Service d'infectiologie - Hôpital Nord / CHU Saint Etienne
        • Kontakt:
        • Hauptermittler:
          • Elisabeth BOTHELO-NEVERS, Pr
      • Toulouse, Frankreich, 31059
        • Rekrutierung
        • Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse
        • Hauptermittler:
          • Laurent ALRIC, Pr
        • Kontakt:
      • Valence, Frankreich, 26000
        • Rekrutierung
        • Service de Maladies Infectieuses - CH de Valence
        • Kontakt:
        • Hauptermittler:
          • Amélie DUREAULT, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adult patient ≥18 years of age

  • ≥3rd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in stool by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI or 2nd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in the stools by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI with at least one of the following risk factors:

    • Age ≥70 years
    • Chronic renal failure (haemodialysis or GFR<60ml/min
    • History of severe or severe-complicated CDI (excluding current episode) according to ESCMID 2021 criteria
    • ≥3 CDI in the last 12 months (including current episode)
    • CDI associated with care defined as CDI occurring during hospitalisation (<3 months)
  • On current or planned vancomycin treatment per os

  • Patient able to give free, informed and written consent

  • Enrolled in compulsory national social security scheme

Exclusion Criteria:

  • Currently participating or has participated in a study with an investigational compound or device within 3 months prior to the first dose of the study intervention.
  • Severe C. difficile infection severe (defined by the presence of a white blood cell count >15×10⁹ cells/L or a body temperature >38.5°C or >50% increase in the patient's baseline creatinine related to CDI at the time of V1) and/or complicated (defined by any of the factors attributed to current Clostridioides difficile infection (CDI): hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, intestinal perforation or any fulminant course of the disease)
  • Refractory C. difficile infection defined as lack of response to well-conducted per os vancomycin or fidaxomicin treatment with ≥3 liquid stools per day after ≥5 days of treatment
  • Cirrhosis with Child C score
  • Hospitalization in continuing care unit or intensive care unit
  • Personal history of gastrointestinal resection other than appendectomy (gastrectomy, esophagectomy, colonic or small bowel resection, short small bowel syndrome).
  • Personal history of gastrointestinal resection resulting in chronic diarrhea (>3 loose stools per day)
  • Inflammatory bowel disease
  • Proven uncontrolled celiac disease
  • Current stoma (ileostomy or colostomy) or within the last 6 months, or any other intra-abdominal surgery within the 3 months prior to treatment
  • major surgery or trauma ≤ 4 weeks before the start of treatment or, if > 4 weeks ago, with an unresolved healing process that could affect the assessment or safety of the study treatment.
  • Antibiotic therapy in progress or planned during the study for an infection other than CDI
  • Surgery scheduled during the study requiring perioperative antibiotics.
  • -Women without contraception*, pregnant or breastfeeding women
  • History of hypersensitivity to EXL01 and/or to any of its excipients (D-mannitol, sucrose, maltodextrin, L-cysteine, L-cysteine hydrochloride, magnesium stearate and hydroxypropylmethylcellulose), and/or to soy or soy-containing products.
  • History of hypersensitivity to vancomycin as mentioned in local prescribing information.
  • Personal history of fecal microbiota transplantation < 6 months
  • Persons deprived of liberty by judicial or administrative decision
  • Adults under legal protection or unable to give consent
  • Swallowing disorders making oral treatment impossible
  • Participation in another interventional study within 3 months prior to inclusion. (Patients who have entered the follow-up phase of an interventional study may participate provided that more than 3 months have elapsed since the last intervention).
  • Expected life expectancy of less than 6 months
  • Presents a known psychiatric disorder that would interfere with adequate cooperation with study requirements.
  • Regular use of illicit or recreational drugs that may interfere with the administration of the medication or the interpretation of the data
  • History of chronic diarrhea (> 3 watery stools per day for > 4 weeks) not related to gastrointestinal infection.
  • Clinically significant medical or surgical condition not mentioned in the above criteria which, in the opinion of the investigator, could interfere with the administration of study drug, the interpretation of study safety or efficacy data, or compromise the safety or well-being of the subject.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Teil A (Open-Label EXL01)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
Experimental: Teil B (EXL01)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
Placebo-Komparator: Teil B (Placebo)

Following a at least 10-days vancomycin treatment:

Oral placebo including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Treatment-Emergent Adverse Events
Zeitfenster: at Week 1, Week 2, Week 4, Week 8, Week 16

Phase I The primary endpoint is the occurrence of serious adverse events (CTCAE grade≥3) during treatment and follow-up and discontinuation of treatment due to adverse events attributed to treatment

at Week 1, Week 2, Week 4, Week 8, Week 16
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Zeitfenster: at Week 8

Phase II The primary endpoint is the proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of CDI-specific treatment.

at Week 8

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Zeitfenster: at Week 8

Phase I Proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of specific treatment for CDI.

at Week 8
Evaluation of the safety and tolerability profile of oral EXL01
Zeitfenster: at Week 2, Week 4, Week 8, Week 16

Phase II Occurrence of adverse events (CTCAE grade≥3) during treatment and follow-up, and discontinuation of treatment due to adverse events

at Week 2, Week 4, Week 8, Week 16
Number of stools per day over the past 24 hours
Zeitfenster: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Zeitfenster: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Zeitfenster: at Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Number of stools per day over the past 24 hours
Zeitfenster: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Zeitfenster: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Zeitfenster: at Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Assessment of patient quality of life during treatment and follow-up
Zeitfenster: At Week 8 and Week 16

Phases I and II Patient quality of life at W8 and M4 measured by a validated digestive disease quality of life questionnaire (GIQLI)

At Week 8 and Week 16
Assessment of recurrence of C. difficile infection
Zeitfenster: At Week 16

Phases I and II percentage of patients with recurrence of C. difficile infection at M4

At Week 16
Evaluation of the presence of EXL01 in the fecal microbiota
Zeitfenster: At Week 8

Phases I and II Level of F. prausnitzii (qPCR) in stool at W8 versus W0

At Week 8
Assessment of EXL01 persistence in the intestinal microbiota
Zeitfenster: At Week 0 and Week 16

Phases I and II Level of F. prausnitzii (qPCR) in stool at M4 versus W0

At Week 0 and Week 16
16S rRNA sequencing or shotgun
Zeitfenster: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Gut microbiota composition at each visit

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
16S rRNA sequencing or shotgun
Zeitfenster: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Gut microbiota composition at each visit

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Zeitfenster: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Zeitfenster: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of recurrences of C. difficile infection requiring hospitalization
Zeitfenster: At Week 8

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at W8

At Week 8
Assessment of recurrences of C. difficile infection requiring hospitalization
Zeitfenster: at Week 16

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at M4

at Week 16
Assessment of recurrences of C. difficile infection requiring surgery
Zeitfenster: at Week 8

phases I and II phases I and II percentage of patients with a recurrence of C. difficile infection requiring surgery at W8

at Week 8
Assessment of recurrences of C. difficile infection requiring surgery
Zeitfenster: at Week 16

phases I and II percentage of patients with recurrent C. difficile infection requiring surgery at M4

at Week 16

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Nicolas BENECH, MD, Hospices Civils de Lyon

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

7. Mai 2024

Primärer Abschluss (Geschätzt)

7. Januar 2028

Studienabschluss (Geschätzt)

7. Januar 2028

Studienanmeldedaten

Zuerst eingereicht

21. Februar 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. März 2024

Zuerst gepostet (Tatsächlich)

12. März 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 69HCL22_0980
  • 2023-506232-32-00 (Andere Kennung: EU CT Number)
  • 2023 (US NIH Stipendium/Vertrag)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .